Atopic Dermatitis Treatment Market Surpasses 30 Trillion Won as Competition Heats Up for Next-Generation Mechanisms
Nemlurio Set for Domestic Launch, Directly Targets "Itching"
Sanofi's Dupixent Successor Completes Phase 3 Trials
Chong Kun Dang and Samsung Bioepis Accelerate Biosimilar Development
Last year, the atopic dermatitis treatment market surpassed 30 trillion won, and a fierce competition for new drugs with diverse mechanisms is now underway. Global pharmaceutical companies are accelerating the development of next-generation treatments that could surpass Dupixent (ingredient: dupilumab), which currently dominates the atopic dermatitis treatment market. Their strategy is to differentiate from existing therapies by directly targeting specific symptoms or causes of immune responses.
According to the pharmaceutical and biotech industry on March 19, the introduction of new atopic dermatitis drugs from global pharmaceutical companies both domestically and internationally is accelerating the market’s restructuring. Galderma’s Nemolizumab (ingredient: nemolizumab), scheduled for domestic launch in the second half of the year, is drawing attention for its distinct mechanism compared to the market leader, Dupixent. While Dupixent suppresses overall inflammatory responses by blocking interleukin (IL)-4 and IL-13 signaling, Nemolizumab blocks the IL-31 receptor to directly inhibit itching. IL-31 is a major cause of pruritus in atopic patients, and it is believed that Nemolizumab can differentiate itself from existing treatments in terms of the speed of symptom improvement.
Sanofi, which developed Dupixent, the world’s top-selling treatment, is working on the next-generation therapy “amlitelimab.” Amlitelimab suppresses T-cell activation itself by blocking the protein OX40L, which is involved in the activation of immune cells. Traditional IL inhibitors work by blocking inflammatory signaling pathways, but amlitelimab intervenes at the initial stages of the immune response to control the onset of inflammation itself. This “higher-level target strategy” is expected to deliver a more fundamental disease control effect. Amlitelimab recently completed Phase 3 clinical trials, bringing it closer to commercialization.
New mechanisms are also being developed for topical treatments applied directly to the skin. Danish pharmaceutical company LEO Pharma will launch the topical JAK (Janus kinase) inhibitor Delgocitinib (brand name: Enzypgo) in Korea this month. JAK inhibitors suppress various inflammatory responses simultaneously by blocking signaling pathways inside cells. For patients receiving topical treatment, this approach is more convenient because it acts directly on the lesion area, unlike injectable or oral treatments. Enzypgo is also evaluated as an alternative that can reduce the burden of long-term therapy, as it operates through a non-steroidal mechanism.
Domestic pharmaceutical companies are also entering the atopic dermatitis treatment market by developing biosimilars. Chong Kun Dang, Samsung Bioepis, Kyungdong Pharmaceutical, and Daewoong Pharmaceutical are all expanding their related pipelines. Chong Kun Dang’s “CKD-706” received approval for Phase 1 clinical trials in Europe earlier this year, while Samsung Bioepis’s “SB33” is under development in the preclinical stage. Kyungdong Pharmaceutical and Daewoong Pharmaceutical are also working to secure candidate substances.
The atopic dermatitis treatment market has experienced rapid growth in recent years. According to market research firm Global Market Insights (GMI), the global atopic dermatitis treatment market surpassed 20 billion US dollars (approximately 30.05 trillion won) last year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
With the growing number of patients and the increasing variety of therapeutic options, this market expansion trend is expected to continue. According to the World Allergy Organization (WAO), the global population of atopic dermatitis patients exceeded 230 million as of 2024. In Korea, the number of patients increased from about 920,000 in 2018 by an average of approximately 4% per year, surpassing 1 million for the first time in 2024. A professor at a university hospital in the Seoul metropolitan area said, “As patients have more treatment options, a greater variety of therapeutic strategies will be used in clinical practice.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.